secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001387131-23-006126
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q1 net loss $33M, cash $72M; Phase 3 TNX-102 SL topline due Q4 2023
-------------------------------------------------------------------------

- Net loss $33.0M ($0.52 per share) vs $26.4M ($1.61) in Q1 2022; cash $72.0M at Mar 31, 2023, down from $120.2M at Dec 31, 2022.
- R&D expenses $26.5M (up from $18.4M) due to advancing clinical programs; G&A decreased to $7.4M from $8.0M.
- Cash used in operations $32.9M vs $31.0M; share repurchase of 16.7M shares at $0.82 avg for $13.6M.
- Pipeline: TNX-102 SL Phase 3 RESILIENT topline expected Q4 2023; TNX-601 ER Phase 2 enrolling; TNX-1900 Phase 2 enrolling.
- Company reallocated resources to focus on late-stage CNS programs; delayed PTSD study in Kenya and reduced COVID-19 investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/0001387131-23-006126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/tnxp_8k-050823.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-006126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer